N/A N=127 The Human Papilloma Virus Effect on Sexual Life
Human Papillomavirus Infection
Primary: Female Sexual Function Index (FSFI) Score — 0.8; 1.2; 0.9; 0.7 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=57 M7824 in Subjects With HPV Associated Malignancies
Human Papilloma Virus · Cervical Cancer · Oropharyngeal Cancer
Primary: Percentage of Participants That Achieved an Objective Confirmed Complete or Partial Overall Tumor Response — 31; 7.7 percentage of participants
Phase 2 N=29 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
Cervical Cancer · Oropharyngeal Cancer · Vaginal Cancer
Primary: Number of Participants With an Objective Clinical Response — 3; 2; 2; 0 Participants
Phase 2 N=18 HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma
HPV-Related Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma
Primary: Progression-free Survival (PFS) at 2 Years — 75.5 percentage of patients
N/A N=33 HPV DNA Testing Through Mobile Mammography Unit
Cervical Cancer
Primary: Acceptability of Self-Collection Paired With Mobile Mammography — 33 Participants
Phase 2 N=35 Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer
Head and Neck Cancer · Human Papilloma Virus
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 15; 9; 11; 4 Participants
Phase 3 N=798 Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.
Infections, Papillomavirus · Papillomavirus Vaccines
Primary: Number of Seroconverted (SCR) Subjects for Anti-Human Papillomavirus Type 16 (Anti-HPV-16) and Anti-Human Papillomavirus Type 18 (Anti-HPV-18) — 118; 127; 126; 371…
Phase 4 N=56 Postpartum HPV Vaccination
HPV-Related Malignancy
Primary: Patient Indication of Willingness to Accept the Vaccine Based on Survey — 56 Participants
Phase 2 N=11 Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer
Cancer of Head and Neck · Cancer of Cervix · Cancer of Anus
Primary: Number of Participants With Dose Limiting Toxicity (DLT) [Phase 1b] — 0 Participants
N/A N=467 HPV Test-and-Treat-Strategy Versus Cytology-based Strategy for Prevention of CIN2+ in HIV-Infected Women
HIV-1 Infection
Primary: Cumulative Rate of Cervical Intraepithelial Neoplasia (CIN2+) (CIN2, CIN3 or Invasive Cancer) by Week 130 — 24.9; 26.5 Events per 100 persons
N/A N=32 The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata
HIV Positive · Anal Condylomata · Anal Warts
Primary: The Primary Endpoint of This Study is Persistence and Recurrence of Anal Warts as Compared Between the Experimental and Control Groups. — 1; 1 participants
Phase 2 N=195 P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC
Carcinoma, Squamous Cell · Head and Neck Neoplasms · Oropharyngeal Neoplasms
Primary: Progression Free Survival (PFS) — 3; 6; 0; 8 Participants
Phase 3 N=666 Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18
Infections, Papillomavirus
Primary: Number of Seroconverted Subjects for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies, in Women 15 to 25 Years of…
Phase 2 N=26 Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer
Oropharynx Squamous Cell Carcinoma
Primary: Progression-free Survival (PFS) — 65 percentage of patients
Phase 4 N=225 HPV Vaccination Study in Postpartum Women
HPV · Immunization · Human Papilloma Virus
Primary: Immunogenicity of a Two-dose 9-valent HPV Vaccination as Assessed by Antibody Titer — 7177.6 mMU/mL
Phase 2 N=15 ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck · HPV Positive Oropharyngeal Squamous Cell Carcinoma
Primary: HPV-Specific T Cell Response Rate — 0.333 proportion of participants
Phase 2 N=42 Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer
Cervical Adenocarcinoma · Cervical Squamous Cell Carcinoma · Human Papillomavirus Infection
Primary: Number of Adverse Events, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 — 56 Adverse Events
Phase 1 N=12 Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
Effects of Immunotherapy · Metastatic/Recurrent Cervical Cancer · Cervical Adenocarcinoma
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 1; 0 Participants
Phase 3 N=100 Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years
Infections, Papillomavirus
Primary: Number of Cytokine-positive CD4/CD8 Cells Per Million in Tests Producing at Least 2 Different Cytokines — 877.4; 19.5; 738.5; 22.3 cells per million CD4/CD8 T-cells
Phase 2 N=12 T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
Vaginal Cancer · Cervical Cancer · Anal Cancer
Primary: Maximum Tolerated Dose (MTD) — 2 # of cells x 10^11
N/A N=609 Men's Beliefs About Associations Between HPV, Cancers, and HPV Vaccination
Anus Neoplasms
Primary: Willingness to Receive the Human Papillomavirus (HPV) Vaccine — 338 Participants
N/A N=12 Ribavirin for Patients With Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies
Human Papillomavirus (HPV)-Related Malignancies · Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies
Primary: Radiographic Responses, Determined by RECIST 1.1 Criteria — 5; 4; 3 Participants
Phase 3 N=770 Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women
Papillomavirus Type 16/18 Infection · Cervical Intraepithelial Neoplasia
Primary: Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 1440.4; 1903.7; 3861.7; 1397.5 EL.U/mL
Phase 3 N=397 Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.
Infections, Papillomavirus · Papillomavirus Vaccines
Primary: Number of Seroconverted Subjects With Anti-HPV-16/18 Antibody Titers Equal to or Above Cut-off Values. — 353; 358 Subjects
Phase 2 N=383 Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine
Infections, Papillomavirus · Papillomavirus Vaccines
Primary: Number of Seroconverted Subjects Against Human Papillomavirus-16 (HPV-16) Antibodies. — 27; 10; 9; 8 subjects
Phase 2 N=48 E7 TCR T Cells for Human Papillomavirus-Associated Cancers
Papillomavirus Infections · Cervical Intraepithelial Neoplasia · Carcinoma In Situ
Primary: Phase II: Overall Response Rate Partial Response + Complete Response (PR +CR) — 0; 5 Participants
N/A N=329 Human Papillomavirus Infection and Virus Genotyping in Uterine Cervix Cancer in Venezuela
Cervical Cancer
Primary: HPV Identification — 95; 142; 78 biopsies
N/A N=112 The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL)
Human Papilloma Virus · Oropharyngeal Squamous Cell Carcinoma
Primary: Disease Specific Survival (DSS) — 29; 15; 15 participants
Phase 3 N=575 Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women
HIV Infections
Primary: Time to the First New Persistent Infection of HPV 6, 11, 16, or 18 — 1.90; 1.04; 2.92; 2.05 Years — p=0.350
Phase 3 N=18,644 Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18
Infections, Papillomavirus
Primary: Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With HPV-16 and/or -18 Cervical Infection in Subjects HPV DNA…